History

SS-31 came out of the Szeto-Schiller peptide series, named for inventors Hazel Szeto (Weill Cornell) and Peter Schiller (Montreal). Per Weill Cornell, the four-amino-acid compound that penetrated cells and concentrated in mitochondria was a serendipitous 2004 discovery that revealed cardiolipin as a novel drug target. Szeto founded Stealth Peptides in 2006 (later Stealth BioTherapeutics), which licensed the compound from Cornell that year. Branded Bendavia in early cardiac trials, then elamipretide, it moved through negative studies in heart attack (2015), mitochondrial myopathy (2023), and dry AMD before earning FDA accelerated approval for Barth syndrome as FORZINITY in September 2025.

SS-31, now approved as the drug elamipretide, is one of the more instructive case studies on this site. It is not a gray-market unknown invented by supplement marketers — it is a real molecule that went through real, rigorous clinical trials. The honest lesson is what those trials showed: across its three largest, best-designed studies the compound missed its primary endpoints, and its single FDA approval is a narrow, conditional one for an ultra-rare genetic disease. The gap between that reality and how SS-31 is sold online for “mitochondrial health” and anti-aging is wide.

What it is

SS-31 is a synthetic, cell-penetrating tetrapeptide — just four amino acids, written D-Arg-Dmt-Lys-Phe-NH2. The use of a D-arginine and a modified (dimethyl) tyrosine makes it resistant to enzymatic breakdown, and the alternating aromatic and basic residues let it cross membranes. Its defining feature is where it goes and what it binds: it concentrates selectively in the inner mitochondrial membrane and binds cardiolipin, the signature phospholipid of that membrane.

By stabilizing cardiolipin, SS-31 is proposed to preserve the folded cristae structure of mitochondria, support assembly of the electron-transport chain, increase ATP production, reduce reactive oxygen species, and keep cytochrome c anchored (which limits a key apoptosis trigger). This mechanism is well characterized in the lab. It also explains why Barth syndrome is the most coherent target: Barth is caused by mutations in the TAFAZZIN gene that disrupt cardiolipin remodeling, so a cardiolipin-stabilizing drug has a specific, logical rationale there.

The claims

There are two very different sets of claims. The legitimate clinical program (run by Stealth BioTherapeutics) studied elamipretide for Barth syndrome, primary mitochondrial myopathy, dry age-related macular degeneration (geographic atrophy), heart failure, and acute heart attack.

The gray-market story is broader and largely unsupported. Research-peptide vendors and biohackers pitch SS-31 for “mitochondrial health,” anti-aging, more energy, faster exercise recovery, and cardiac or cognitive “optimization.” None of these healthy-person performance or longevity uses are backed by controlled human evidence.

The evidence

A pattern is worth flagging up front: across its three largest, best-designed trials, elamipretide failed its primary endpoints. Its sole approval rests on an open-label strength signal in roughly ten patients. Most of the positive data come from company-sponsored studies.

Barth syndrome (TAZPOWER) — the basis for approval. This was a randomized, double-blind, placebo-controlled crossover trial in just 12 patients, followed by an open-label extension. The controlled, randomized phase failed both primary endpoints: the six-minute walk test differed by only −0.8 meters (p=0.97), and a fatigue score barely moved (p=0.89). The improvements that supported approval came afterward, in the uncontrolled open-label extension, where patients walked a cumulative 96.1 meters farther by week 168 and knee-extensor strength improved. That open-label, single-arm design has no placebo comparator and is prone to bias. The FDA accepted knee-extensor strength as an intermediate clinical endpoint under accelerated approval and explicitly required a confirmatory trial.

Primary mitochondrial myopathy (MMPOWER-3). This was the pivotal Phase 3: randomized, double-blind, placebo-controlled, 218 patients (109 on drug, 109 on placebo), 24 weeks. It was negative. The six-minute walk test differed by −3.2 meters between groups (not significant), and there was no benefit on fatigue. A post-hoc subgroup analysis (patients with nuclear-DNA variants) hinted at possible benefit, but that is hypothesis-generating only and cannot substitute for a met primary endpoint.

Dry AMD / geographic atrophy (ReCLAIM-2). This Phase 2 randomized trial also missed its primary endpoints (low-luminance visual acuity and lesion progression). A secondary signal — about a 43% reduction in attenuation of the retina’s ellipsoid zone versus placebo — was described as promising but is not confirmatory.

Cardiology (Bendavia era). EMBRACE-STEMI tested intravenous elamipretide in 118 patients having a heart attack and was negative for its primary endpoint; it did not reduce infarct size. The heart-failure program (PROGRESS-HF) likewise did not meet its primary endpoint of reducing left-ventricular volume.

Animal data. There is a large body of preclinical work in rodent and large-animal models of heart failure, ischemia-reperfusion injury, kidney disease, neurodegeneration, and aging-related mitochondrial decline. This work is mechanistically supportive and is what justified the human trials — but, as those trials show, it has translated to humans inconsistently.

What’s missing. There is no placebo-controlled confirmation of the Barth strength benefit (confirmation is a post-marketing requirement). There is no positive Phase 3 in any common condition. And there is zero controlled human evidence for anti-aging, general energy, athletic performance, or cognition — the exact uses pushed in the gray market.

Safety and side effects

In the clinical trials elamipretide was generally well tolerated, and the most common adverse event was injection-site reactions — redness, hardening, bruising, itching, and pain — usually mild to moderate. The approved FORZINITY label lists injection-site reactions as the most common adverse reactions and notes the product contains benzyl alcohol (a caution in neonates); no boxed warning was identified.

Two important caveats: long-term safety data are limited, because the studied populations were small, the exposures relatively short, and most involved rare-disease patients. And safety in otherwise healthy people using gray-market “research” product is uncharacterized. That gray-market material is not the approved drug — it is not made to pharmaceutical standards, and its purity, potency, and contaminants are unverified.

Legal and regulatory status

On September 19, 2025, the FDA granted accelerated approval to FORZINITY (elamipretide HCl) injection, indicated to improve muscle strength in adult and pediatric Barth syndrome patients weighing at least 30 kg. It is the first FDA-approved therapy for Barth syndrome and the first FDA-approved mitochondria-targeted drug. Continued approval is contingent on a confirmatory trial.

The path there was contested, which matters for credibility. An FDA advisory committee voted only 10–6 (October 10, 2024) that the drug was effective for Barth. The agency then issued a Complete Response Letter (May 15, 2025) before the company resubmitted (August 15, 2025) on the knee-extensor-strength intermediate endpoint, after which accelerated approval followed.

Outside the US, there is no approval anywhere — no EMA, MHRA, or other regulator has cleared it. And outside Barth syndrome, every use is off-label or unapproved. The “research peptide” SS-31 sold online is not FORZINITY.

On anti-doping, the status is genuinely ambiguous. Elamipretide is not individually named on the WADA Prohibited List. Before the 2025 approval it plausibly fell under category S0 (non-approved substances). Now that it has FDA approval, the S0 definition arguably no longer applies — yet it is not listed in any other category either. An athlete should confirm directly with their anti-doping authority and consider a therapeutic use exemption if it is prescribed.

Bottom line

SS-31 / elamipretide is a real drug with a coherent mechanism, a deep animal-data foundation, and genuine human trials — which is more than most compounds on this site can claim. But the verdict from those human trials is sobering: the large pivotal studies in mitochondrial myopathy, heart failure, and dry AMD all failed their primary endpoints, and the one approval is a narrow, accelerated, ultra-rare-disease indication built on an open-label strength signal in about ten patients, still awaiting confirmation. For Barth syndrome there is now regulator-vetted human evidence. For everything else the data are preliminary at best, and for anti-aging or performance there is no credible human evidence at all. Nothing here is medical advice.

Evidence grade: Preliminary human (and “No credible evidence” for any longevity or performance use).

SS-31 (Elamipretide): Real human trials, mostly failed endpoints, one narrow approval